Literature DB >> 23054646

Splicing factor mutations in myelodysplasia.

Seishi Ogawa1.   

Abstract

Myelodysplastic syndromes (MDS) and related myeloid neoplasms are a heterogeneous group of myeloid neoplasms, which frequently terminate in acute myeloid leukemia (AML). During the past decade, a number of gene mutations have been identified in MDS. However, the spectrum of these mutations overlaps largely with that in AML, complicating the understanding of MDS-specific pathogenesis that discriminates MDS from AML. Recently, several groups reported frequent mutations of multiple components of the RNA splicing machinery in MDS and related disorders. Largely specific to myelodysplastic phenotypes, these splicing factor mutations provide a potential clue to better understanding of the pathogenesis of MDS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054646     DOI: 10.1007/s12185-012-1182-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  46 in total

1.  SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications.

Authors:  F Damm; F Thol; O Kosmider; S Kade; P Löffeld; F Dreyfus; A Stamatoullas-Bastard; A Tanguy-Schmidt; O Beyne-Rauzy; S de Botton; A Guerci-Bresler; G Göhring; B Schlegelberger; A Ganser; O A Bernard; M Fontenay; M Heuser
Journal:  Leukemia       Date:  2011-11-08       Impact factor: 11.528

2.  Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1.

Authors:  Kyoichi Isono; Yoko Mizutani-Koseki; Toshihisa Komori; Marion S Schmidt-Zachmann; Haruhiko Koseki
Journal:  Genes Dev       Date:  2005-03-01       Impact factor: 11.361

3.  A common genetic mechanism in malignant bone marrow diseases.

Authors:  Ross L Levine; Martin Carroll
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

4.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Authors:  Valeria Visconte; Heesun J Rogers; Jarnail Singh; John Barnard; Manoj Bupathi; Fabiola Traina; James McMahon; Hideki Makishima; Hadrian Szpurka; Anna Jankowska; Andres Jerez; Mikkael A Sekeres; Yogen Saunthararajah; Anjali S Advani; Edward Copelan; Haruhiko Koseki; Kyoichi Isono; Richard A Padgett; Sami Osman; Kazunori Koide; Christine O'Keefe; Jaroslaw P Maciejewski; Ramon V Tiu
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

Review 5.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

6.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

Review 7.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

8.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

Review 9.  The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.

Authors:  Thomas R Webb; Amanda S Joyner; Philip M Potter
Journal:  Drug Discov Today       Date:  2012-08-03       Impact factor: 7.851

10.  Splicing factor SF3b as a target of the antitumor natural product pladienolide.

Authors:  Yoshihiko Kotake; Koji Sagane; Takashi Owa; Yuko Mimori-Kiyosue; Hajime Shimizu; Mai Uesugi; Yasushi Ishihama; Masao Iwata; Yoshiharu Mizui
Journal:  Nat Chem Biol       Date:  2007-07-22       Impact factor: 15.040

View more
  18 in total

1.  Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis.

Authors:  Sakurako Suma; Mamiko Sakata-Yanagimoto; Tran B Nguyen; Keiichiro Hattori; Taiki Sato; Masayuki Noguchi; Yasuhito Nannya; Seishi Ogawa; Rei Watanabe; Manabu Fujimoto; Naoya Nakamura; Manabu Kusakabe; Hidekazu Nishikii; Takayasu Kato; Shigeru Chiba
Journal:  Int J Hematol       Date:  2018-04-28       Impact factor: 2.490

2.  A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.

Authors:  Yihui Shi; Jaehyeon Park; Chandraiah Lagisetti; Wei Zhou; Lidia C Sambucetti; Thomas R Webb
Journal:  Bioorg Med Chem Lett       Date:  2016-12-24       Impact factor: 2.823

Review 3.  Genomic tools in acute myeloid leukemia: From the bench to the bedside.

Authors:  Brian S White; John F DiPersio
Journal:  Cancer       Date:  2014-01-28       Impact factor: 6.860

Review 4.  Small RNA as a regulator of hematopoietic development, immune response in infection and tumorigenesis.

Authors:  Kazuki Okuyama; Jun Ogata; Natsuko Yamakawa; Bidisha Chanda; Ai Kotani
Journal:  Int J Hematol       Date:  2014-04-01       Impact factor: 2.490

5.  Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.

Authors:  Lee Spraggon; Luca Cartegni
Journal:  Drug Discov Today Ther Strateg       Date:  2013

Review 6.  Mechanisms and Regulation of Alternative Pre-mRNA Splicing.

Authors:  Yeon Lee; Donald C Rio
Journal:  Annu Rev Biochem       Date:  2015-03-12       Impact factor: 23.643

Review 7.  Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.

Authors:  Takayuki Ishikawa
Journal:  Int J Clin Oncol       Date:  2013-12-20       Impact factor: 3.402

8.  Optimization of antitumor modulators of pre-mRNA splicing.

Authors:  Chandraiah Lagisetti; Gustavo Palacios; Tinopiwa Goronga; Burgess Freeman; William Caufield; Thomas R Webb
Journal:  J Med Chem       Date:  2013-12-11       Impact factor: 7.446

9.  A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Authors:  Sophia Adamia; Benjamin Haibe-Kains; Patrick M Pilarski; Michal Bar-Natan; Samuel Pevzner; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; John Burke; Ilene Galinsky; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Richard Stone; James D Griffin
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

10.  RNA-Seq analysis identifies aberrant RNA splicing of TRIP12 in acute myeloid leukemia patients at remission.

Authors:  Panke Gao; Zhen Jin; Yingying Cheng; Xiangshan Cao
Journal:  Tumour Biol       Date:  2014-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.